Drug intelligence / Profile preview

KM-110

Development stage: Preclinical
Modality: Small Molecules
Administration: Intravenous

Overview

KM-110 is an aqueous extract derived from Viscum album coloratum, commonly known as Korean mistletoe. It has demonstrated inhibitory effects on tumor metastasis and angiogenesis in preclinical models. The drug works by suppressing tumor growth and inhibiting the formation of new blood vessels that supply tumors. A key mechanism involves the induction of Tumor Necrosis Factor-alpha (TNF-alpha) activity by stimulating murine peritoneal macrophages, which contributes to its antimetastatic effects. Additionally, KM-110 has been shown to inhibit the growth of rat lung endothelial cells in vitro.

Other names: aqueous extract from Viscum album coloratumKorean mistletoe extract

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on KM-110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KM-110.

Explore the full profile